Not A Loophole? BIO Concerned About Limiting Orphan Designations For Pediatric Subsets of Common Diseases

BIO disagrees with US FDA implying companies are behaving inappropriately, says agency should acknowledge it created problem being addressed in draft guidance.

Guidance word in red keyboard buttons

The Biotechnology Innovation Organization took offense with the US FDA's suggestion that sponsors are exploiting a "loophole" in the Orphan Drug Act to gain an exemption from pediatric studies that otherwise would be mandated.

In comments to recent draft guidance stating that FDA would limit orphan designations in those situations, BIO argues that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet